低风险大麻使用指南:证据与推荐的综合更新
为应对大麻使用相关健康风险,作者系统检索MEDLINE、EMBASE、PsycINFO、Cochrane Library等数据库,聚焦使用者可改变的行为因素,按GRADE标准分级证据,经专家共识制定10条低风险使用推荐,涵盖 abstinence、避免16岁前开始使用、选择低效价或THC与CBD平衡产品、避免合成大麻素、避免燃烧吸入、避免深度吸入、避免高频使用、避免大麻影响下驾驶、高风险人群避免使用及避免风险行为叠加。
要点
- 避免大麻使用相关健康风险最有效的方式是戒断不使用。
- 明确避免在16岁前开始使用大麻,选择低效价THC或THC与CBD平衡产品。
- 避免合成大麻素、燃烧吸入、深度吸入、高频使用及大麻影响下驾驶,高风险人群应避免使用。
核心结论
- 证据表明,使用者通过知情行为选择可在相当程度上降低大麻使用相关不良健康结局的风险。
- 基于证据的低风险大麻使用指南可作为人群层面的教育与干预工具,引导使用者选择以改善公共卫生结局。
- 该指南需通过产品标签、内容监管等关键监管措施系统传播与支持方可有效,监管机构应积极实施,并应评估其人群影响。
研究设计与样本
- 系统综述与专家共识:检索MEDLINE、EMBASE、PsycINFO、Cochrane Library数据库及参考文献列表,主要纳入系统综述与Meta分析及可改变风险因素的补充证据。
- 纳入标准为聚焦大麻使用健康风险或危害的可改变行为因素的研究,排除以治疗为目的评估大麻使用的研究。
- 由2名作者独立提取纳入研究数据,按GRADE标准对证据进行质量分级,经作者专家集体迭代共识流程转化为推荐。
主要发现
- 多数推荐至少有「实质性」(即良好质量)证据支持。
- 共制定10条主要推荐:戒断;避免16岁前开始使用;选择低效价THC或THC与CBD平衡产品;避免合成大麻素;避免燃烧吸入并优先非吸烟方式;避免深度或其他危险吸入方式;避免高频(如每日或近乎每日)使用;避免大麻影响下驾驶;高风险人群避免使用;避免上述风险行为叠加。
关键数值与推荐
- 推荐1:避免大麻使用相关健康风险最有效的方式是戒断不使用。
- 推荐2:避免早年(明确16岁前)开始使用大麻。
- 推荐3:选择低效价四氢大麻酚(THC)或THC与大麻二酚(CBD)平衡比例的大麻产品。
- 推荐4:戒断不使用合成大麻素。
- 推荐5:避免燃烧吸入大麻,优先选择非吸烟使用方式。
临床怎么用
- 低风险大麻使用指南可作为人群层面的教育与干预工具,引导使用者做出知情行为选择以改善公共卫生结局。
- 该指南应通过大麻产品标签、内容监管等关键监管措施系统传播与支持,方可有效。
- 监管机构应在不断演变的法律化框架下积极实施上述措施,并应评估该指南对降低大麻使用相关健康风险的人群影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cannabis use is common in North America, especially among young people, and is associated with a risk of various acute and chronic adverse health outcomes. Cannabis control regimes are evolving, for example toward a national legalization policy in Canada, with the aim to improve public health, and thus require evidence-based interventions. As cannabis-related health outcomes may be influenced by behaviors that are modifiable by the user, evidence-based Lower-Risk Cannabis Use Guidelines (LRCUG)-akin to similar guidelines in other health fields-offer a valuable, targeted prevention tool to improve public health outcomes. OBJECTIVES: To systematically review, update, and quality-grade evidence on behavioral factors determining adverse health outcomes from cannabis that may be modifiable by the user, and translate this evidence into revised LRCUG as a public health intervention tool based on an expert consensus process. SEARCH METHODS: We used pertinent medical search terms and structured search strategies, to search MEDLINE, EMBASE, PsycINFO, Cochrane Library databases, and reference lists primarily for systematic reviews and meta-analyses, and additional evidence on modifiable risk factors for adverse health outcomes from cannabis use. SELECTION CRITERIA: We included studies if they focused on potentially modifiable behavior-based factors for risks or harms for health from cannabis use, and excluded studies if cannabis use was assessed for therapeutic purposes. DATA COLLECTION AND ANALYSIS: We screened the titles and abstracts of all studies identified by the search strategy and assessed the full texts of all potentially eligible studies for inclusion; 2 of the authors independently extracted the data of all studies included in this review. We created Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow-charts for each of the topical searches. Subsequently, we summarized the evidence by behavioral factor topic, quality-graded it by following standard (Grading of Recommendations Assessment, Development, and Evaluation; GRADE) criteria, and translated it into the LRCUG recommendations by the author expert collective on the basis of an iterative consensus process. MAIN RESULTS: For most recommendations, there was at least "substantial" (i.e., good-quality) evidence. We developed 10 major recommendations for lower-risk use: (1) the most effective way to avoid cannabis use-related health risks is abstinence, (2) avoid early age initiation of cannabis use (i.e., definitively before the age of 16 years), (3) choose low-potency tetrahydrocannabinol (THC) or balanced THC-to-cannabidiol (CBD)-ratio cannabis products, (4) abstain from using synthetic cannabinoids, (5) avoid combusted cannabis inhalation and give preference to nonsmoking use methods, (6) avoid deep or other risky inhalation practices, (7) avoid high-frequency (e.g., daily or near-daily) cannabis use, (8) abstain from cannabis-impaired driving, (9) populations at higher risk for cannabis use-related health problems should avoid use altogether, and (10) avoid combining previously mentioned risk behaviors (e.g., early initiation and high-frequency use). AUTHORS' CONCLUSIONS: Evidence indicates that a substantial extent of the risk of adverse health outcomes from cannabis use may be reduced by informed behavioral choices among users. The evidence-based LRCUG serve as a population-level education and intervention tool to inform such user choices toward improved public health outcomes. However, the LRCUG ought to be systematically communicated and supported by key regulation measures (e.g., cannabis product labeling, content regulation) to be effective. All of these measures are concretely possible under emerging legalization regimes, and should be actively implemented by regulatory authorities. The population-level impact of the LRCUG toward reducing cannabis use-related health risks should be evaluated. Public health implications. Cannabis control regimes are evolving, including legalization in North America, with uncertain impacts on public health. Evidence-based LRCUG offer a potentially valuable population-level tool to reduce the risk of adverse health outcomes from cannabis use among (especially young) users in legalization contexts, and hence to contribute to improved public health outcomes.
引用
- Fischer B, Russell C, Sabioni P, et al. Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. Am J Public Health. 2017. PMID: 28644037. doi:10.2105/AJPH.2017.303818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。